TY  - GEN
AU  - Azad,Nilofer S
AU  - Posadas,Edwin M
AU  - Kwitkowski,Virginia E
AU  - Steinberg,Seth M
AU  - Jain,Lokesh
AU  - Annunziata,Christina M
AU  - Minasian,Lori
AU  - Sarosy,Gisele
AU  - Kotz,Herbert L
AU  - Premkumar,Ahalya
AU  - Cao,Liang
AU  - McNally,Deborah
AU  - Chow,Catherine
AU  - Chen,Helen X
AU  - Wright,John J
AU  - Figg,William D
AU  - Kohn,Elise C
TI  - Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
SN  - 1527-7755
PY  - 2008///0814
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Angiogenesis Inhibitors
KW  - administration & dosage
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Benzenesulfonates
KW  - Bevacizumab
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Neoplasms
KW  - drug therapy
KW  - Niacinamide
KW  - analogs & derivatives
KW  - Ovarian Neoplasms
KW  - Phenylurea Compounds
KW  - Protein Kinase Inhibitors
KW  - Pyridines
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - antagonists & inhibitors
KW  - Sorafenib
KW  - Treatment Outcome
KW  - Vascular Endothelial Growth Factor A
KW  - raf Kinases
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural
UR  - https://doi.org/10.1200/JCO.2007.10.8332
ER  -